Bioheart, Inc. (NasdaqCM: BHRT) announced today it has filed with appropriate agencies in Italy, Germany and the Netherlands for reimbursement approval for its MyoCell® myogenic cell therapy for heart failure. This patented composition and method has been studied in clinical trials involving more than 350 patients to date at over 100 centers worldwide since the year 2000.

Bioheart, Inc. (Nasdaq: BHRT), a pioneer in the biotechnology field with their “myoblast” muscle stem cell therapy for heart failure patients, recently announced that the company has received a Notice of Allowance from the US Patent and Trademark Office for nine new patents.

Bioheart, Inc., (NasdaqCM: BHRT), is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. To achieve this goal, BHRT recently announced it has received an aggregate of approximately $1.8 million in cash from accredited investors, including existing shareholders. The proceeds from the private placement will be used for Bioheart’s ongoing clinical and business operations, as the Company continues to actively pursue additional investment support.

A preclinical study involving the injection of adipose-derived stem cells (ADSCs) into the myocardium (heart muscle tissue) of infarcted rats, was recently completed.